Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Depreciation and Depletion (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Depreciation and Depletion for 15 consecutive years, with $700000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion changed 0.0% to $700000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.8 million, a 16.67% increase, with the full-year FY2024 number at $2.5 million, up 38.89% from a year prior.
  • Depreciation and Depletion was $700000.0 for Q3 2025 at Xtant Medical Holdings, down from $800000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $800000.0 in Q2 2025 to a low of $200000.0 in Q4 2022.
  • A 5-year average of $468421.1 and a median of $400000.0 in 2021 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: crashed 42.86% in 2021, then skyrocketed 200.0% in 2023.
  • Xtant Medical Holdings' Depreciation and Depletion stood at $300000.0 in 2021, then crashed by 33.33% to $200000.0 in 2022, then surged by 200.0% to $600000.0 in 2023, then rose by 16.67% to $700000.0 in 2024, then changed by 0.0% to $700000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Depreciation and Depletion are $700000.0 (Q3 2025), $800000.0 (Q2 2025), and $600000.0 (Q1 2025).